Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver Disease
Microbiome-derived short chain fatty acids (SCFAs: acetate, propionate, and butyrate) and bile acids (BAs: primary BAs and secondary BAs) widely influence liver metabolic inflammation, immune responses, and carcinogenesis. In recent literature, the role of SCFAs and BAs in various liver diseases has...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Livers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-4389/2/3/12 |
| _version_ | 1797485659621949440 |
|---|---|
| author | Raja Ganesan Ki Tae Suk |
| author_facet | Raja Ganesan Ki Tae Suk |
| author_sort | Raja Ganesan |
| collection | DOAJ |
| description | Microbiome-derived short chain fatty acids (SCFAs: acetate, propionate, and butyrate) and bile acids (BAs: primary BAs and secondary BAs) widely influence liver metabolic inflammation, immune responses, and carcinogenesis. In recent literature, the role of SCFAs and BAs in various liver diseases has been discussed. SCFAs and BAs are two types of microbiome-derived metabolites and they have been shown to have immunoregulatory ability in autoimmunity, inflammation, and liver-cancer microcellular environments. SCFAs and BAs are dependent on dietary components. The numerous regulatory processes in lymphocytes and non-immune cells that underpin both the positive and harmful effects of microbial metabolites include variations in metabolic signaling and epigenetic states. As a result, histone deacetylase (HDAC) inhibitors, SCFAs, and BAs, which are powerful immunometabolism modulators, have been explored. BAs have also been shown to alter the microbiome as well as adaptive and innate immune systems. We therefore emphasize the important metabolites in liver disease for clinical therapeutic applications. A deep understanding of SCFAs and Bas, as well as their molecular risk, could reveal more about certain liver-disease conditions. |
| first_indexed | 2024-03-09T23:22:59Z |
| format | Article |
| id | doaj.art-f735052d37fe4e4bbf2d2d5f60538d35 |
| institution | Directory Open Access Journal |
| issn | 2673-4389 |
| language | English |
| last_indexed | 2024-03-09T23:22:59Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Livers |
| spelling | doaj.art-f735052d37fe4e4bbf2d2d5f60538d352023-11-23T17:24:33ZengMDPI AGLivers2673-43892022-08-012313914510.3390/livers2030012Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver DiseaseRaja Ganesan0Ki Tae Suk1Institute for Liver and Digestive Disease, Hallym University, Chuncheon 24253, KoreaInstitute for Liver and Digestive Disease, Hallym University, Chuncheon 24253, KoreaMicrobiome-derived short chain fatty acids (SCFAs: acetate, propionate, and butyrate) and bile acids (BAs: primary BAs and secondary BAs) widely influence liver metabolic inflammation, immune responses, and carcinogenesis. In recent literature, the role of SCFAs and BAs in various liver diseases has been discussed. SCFAs and BAs are two types of microbiome-derived metabolites and they have been shown to have immunoregulatory ability in autoimmunity, inflammation, and liver-cancer microcellular environments. SCFAs and BAs are dependent on dietary components. The numerous regulatory processes in lymphocytes and non-immune cells that underpin both the positive and harmful effects of microbial metabolites include variations in metabolic signaling and epigenetic states. As a result, histone deacetylase (HDAC) inhibitors, SCFAs, and BAs, which are powerful immunometabolism modulators, have been explored. BAs have also been shown to alter the microbiome as well as adaptive and innate immune systems. We therefore emphasize the important metabolites in liver disease for clinical therapeutic applications. A deep understanding of SCFAs and Bas, as well as their molecular risk, could reveal more about certain liver-disease conditions.https://www.mdpi.com/2673-4389/2/3/12short-chain fatty acidsbile acidsliver therapiesmetabolomicsmetabolic discriminationsbiochemistry |
| spellingShingle | Raja Ganesan Ki Tae Suk Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver Disease Livers short-chain fatty acids bile acids liver therapies metabolomics metabolic discriminations biochemistry |
| title | Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver Disease |
| title_full | Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver Disease |
| title_fullStr | Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver Disease |
| title_full_unstemmed | Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver Disease |
| title_short | Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver Disease |
| title_sort | therapeutic potential of human microbiome based short chain fatty acids and bile acids in liver disease |
| topic | short-chain fatty acids bile acids liver therapies metabolomics metabolic discriminations biochemistry |
| url | https://www.mdpi.com/2673-4389/2/3/12 |
| work_keys_str_mv | AT rajaganesan therapeuticpotentialofhumanmicrobiomebasedshortchainfattyacidsandbileacidsinliverdisease AT kitaesuk therapeuticpotentialofhumanmicrobiomebasedshortchainfattyacidsandbileacidsinliverdisease |